Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024 GalleryAgendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrint® as the only commercially Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024 GalleryAgendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrint® in Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical Read More
Agendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics GalleryAgendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
Agendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 Read More
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read More
Agendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read More
MammaPrint High 2 tumors exhibit heightened immune active state
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read More
